Effect of oral magnesium supplementation on insulin sensitivity and blood pressure in apparently healthy overweight adults: a randomised double-blinded controlled trial

INTERVENTION: 12.3 mmol (300 mg) of elemental magnesium per day in the form of magnesium oxide or placebo. The total duration of treatment and the total duration of follow up are both 12 weeks (i.e., no follow‐up). CONDITION: Overweight, obesity ; Nutritional, Metabolic, Endocrine ; Obesity PRIMARY OUTCOME: 1. The HOMeostasis model Assessment of Insulin Resistance (HOMA‐IR) ; 2. Quantitative Insulin Sensitivity Check Index (QUICKI); 3. Systolic BP; 4. Diastolic BP; ; Primary outcomes measured at baseline and 12 weeks (at the end of this study). SECONDARY OUTCOME: 1. Lipids; 2. Serum trace minerals (magnesium, calcium, and phosphorus); ; Secondary outcomes measured at baseline and 12 weeks (at the end of this study). INCLUSION CRITERIA: 1. Aged 30 ‐ 60 years 2. Body mass index greater than or equal to 23 kg/m^2 3. Have not taken any supplements or medications, including anti‐diabetic drugs, anti‐hypertensive drugs, steroids, or hormonal products, during the previous 4 weeks